$4.68
5.17% today
Nasdaq, Apr 02, 10:06 pm CET
ISIN
US00289Y1073
Symbol
ABEO
Sector
Industry

Abeona Therapeutics, Inc. Stock price

$4.68
-0.41 8.06% 1M
-1.55 24.88% 6M
-0.89 15.98% YTD
-2.80 37.43% 1Y
-3.55 43.10% 3Y
-48.07 91.13% 5Y
-74.57 94.09% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.23 5.17%
ISIN
US00289Y1073
Symbol
ABEO
Sector
Industry

Key metrics

Market capitalization $215.98m
Enterprise Value $140.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.61
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-64.21m
Free Cash Flow (TTM) Free Cash Flow $-59.42m
Cash position $98.06m
EPS (TTM) EPS $-2.25
P/E forward negative
P/S forward 18.40
EV/Sales forward 12.01
Short interest 5.16%
Show more

Is Abeona Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Abeona Therapeutics, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy
100%

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 3.89 3.89
22% 22%
-
-3.89 -3.89
1,397% 1,397%
-
- Selling and Administrative Expenses 22 22
55% 55%
-
- Research and Development Expense 34 34
11% 11%
-
-60 -60
34% 34%
-
- Depreciation and Amortization 3.89 3.89
22% 22%
-
EBIT (Operating Income) EBIT -64 -64
33% 33%
-
Net Profit -64 -64
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Abeona Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abeona Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
13 days ago
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Greg Gin – Vice President-Investor Relations and Communications Vish Seshadri – Chief Executive Officer Madhav Vasanthavada – Chief Commercial Officer and Head-Business Development Brian Kevany – Chief Technical Officer Joe Vazzano – Chief Financial Officer Conference Call Par...
Neutral
GlobeNewsWire
13 days ago
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025
More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office United States
CEO Vishwas Seshadri
Employees 136
Founded 1974
Website www.abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today